Drug Repositioning¶

Develop a new therapeutic indication for an existing or previously investigated drug by reusing applicable knowledge while generating the indication-specific evidence still required.

Version: v2 · 2026-09-06 · History
Domain-specific #: 1718
Origin domain: medicine
Subdomain: drug discovery and development
Aliases: Drug repurposing, Drug reprofiling, Therapeutic repositioning

Core Idea¶

Drug repositioning is the investigation and development of an existing or previously investigated drug for a therapeutic indication different from the one that motivated its original development or established use. The starting asset may be approved, shelved, discontinued, generic, or clinically investigated. Repositioning reuses whatever is genuinely transferable—chemistry, manufacturing, pharmacokinetics, toxicology, human exposure, or delivery experience—while generating the evidence needed for the new disease, population, dose, route, formulation, combination, and claim.^[1]

Candidates can arise serendipitously from clinical observation or systematically from target/pathway knowledge, phenotypic screening, omics signatures, genetics, adverse-event signals, electronic health records, molecular docking, network models, or cross-disease mechanisms. Identification is only the beginning: a predicted drug–disease link must survive mechanistic, preclinical, clinical, regulatory, manufacturing, safety, and commercial evaluation.^[2]

The recognition invariant is preexisting drug asset + genuinely new therapeutic use + transferable prior evidence + new-use rationale and validation + indication-specific development plan + regulatory and safety pathway.

Structural Signature¶

Existing asset: known active substance with documented prior investigation or use.
Original context: prior indication, development hypothesis, population, dose, route, and status.
New indication: distinct disease, condition, stage, phenotype, or clinically meaningful use.
Discovery signal: mechanistic, phenotypic, computational, genetic, observational, or serendipitous evidence.
Transferability audit: identifies which prior CMC, PK, toxicology, and clinical data remain applicable.
Evidence gap: new efficacy, dose, formulation, interaction, safety, or population questions.
Validation ladder: orthogonal assays, disease models, biomarkers, and human evidence.
Development pathway: indication-specific trials and endpoints.
Regulatory strategy: lawful reliance on prior findings plus required new evidence.
Safety surveillance: known and indication-specific adverse effects and benefit–risk.
Access and incentives: patents, data exclusivity, supply, licensing, and stewardship.

What It Is Not¶

It is not ordinary off-label prescribing. A clinician may lawfully use an approved drug outside its label without conducting a repositioning development program; repositioning seeks evidence and often authorization for a new use. It is not simply a new brand, dosage form, or generic entrant unless a distinct therapeutic use is being developed.

It is not de novo discovery from an uncharacterized molecule, although repurposing can reveal an unexpected mechanism. Nor is a computational rank list an accomplished repositioning: predictions nominate hypotheses. A failed trial is not proof that the strategy is invalid, and prior approval does not prove safety or efficacy at the new dose and population.

Scope of Application¶

Repositioning is used across common, rare, neglected, infectious, oncologic, neurologic, and psychiatric diseases. It is especially attractive where mechanistic overlap exists, human exposure data are available, development resources are constrained, or a shelved compound has a usable safety margin. Sildenafil, thalidomide, and several oncology and rare-disease uses illustrate different routes from observation to new indication.^[3]

The strategy can shorten or de-risk parts of development, but savings are conditional. A new route, higher exposure, chronic use, pediatric population, pregnancy context, combination, or formulation may reopen substantial nonclinical and Phase I obligations. Generic availability can also weaken the incentive to fund expensive trials.

Clarity¶

“Existing” must be defined. Some programs restrict the term to approved drugs; others include discontinued or clinical-stage assets. The draft should state asset status and whether “repurposing” and “repositioning” are treated as synonyms.

Reused evidence is not a blanket exemption. Transfer depends on active ingredient, impurities, formulation, route, exposure, population, duration, and endpoint. Regulatory reliance routes such as the U.S. 505(b)(2) pathway still require a complete, legally supportable application and whatever new studies bridge the differences.^[4]

Manages Complexity¶

Prior knowledge narrows the search and can bypass some early uncertainties. Drug–target–disease networks organize heterogeneous evidence; target product profiles turn a promising observation into explicit requirements; staged validation retires mechanism, exposure, efficacy, safety, and feasibility risks in sequence.

Repositioning also inherits complex history. Published data can be incomplete, shelved-compound records inaccessible, negative results unpublished, and old formulations unavailable. Integrating evidence without double-counting correlated datasets is as important as finding a high model score.

Abstract Reasoning¶

Define the new clinical need and target product profile.
Establish the asset’s identity, ownership, status, manufacturing route, and prior evidence.
Generate a drug–disease hypothesis through mechanistic or phenotype-linked evidence.
Triangulate the signal across independent data types and rule out artifacts.
Confirm target engagement or phenotypic activity at clinically achievable exposure.
Audit transferable versus nontransferable CMC, PK, toxicology, and trial evidence.
Design dose, route, formulation, biomarker, and patient-selection strategy.
Obtain indication-specific preclinical and clinical evidence with suitable controls.
Address regulatory reliance, patents/exclusivity, supply, and pharmacovigilance.
Update benefit–risk and stop when exposure, efficacy, safety, or feasibility fails.

Knowledge Transfer¶

The transferable pattern is to reuse a partially validated asset in a new problem context while explicitly auditing which guarantees survive the transfer. Platform reuse, technology transfer, and case-based design share that logic.

The proposed immediate parent is Translational Research: repositioning is a specialized route for moving biological and clinical evidence into an evaluated therapy.

Examples¶

Mechanism-led program. Human genetics implicates a disease pathway already modulated by an approved drug; the program verifies exposure and target engagement, then tests a biomarker-defined population.

Phenotype-led program. A screened library of clinically characterized compounds produces a reproducible disease-model rescue; orthogonal assays identify plausible mechanism and prioritize a trial.

Non-example. A social-media claim that an available drug might treat a disease is a hypothesis, not a repositioned therapy.

Structural Tensions¶

Speed and prior knowledge versus indication-specific uncertainty.
Broad computational screening versus causal validation.
Known safety versus new exposure and population risks.
Public-health value versus weak exclusivity incentives.
Rapid access versus randomized evidence.
Reuse of data versus inaccessible or biased history.

Structural–Framed Character¶

Existing asset, new indication, transfer audit, evidence gaps, validation, and development pathway are structural. Disease priority, model choice, endpoint, dose, acceptable risk, regulatory jurisdiction, and commercial strategy are framed.

Structural Core vs. Domain Accent¶

The portable core is qualified reuse under changed requirements. Drugs, targets, indications, pharmacokinetics, toxicology, trials, regulatory submissions, and pharmacovigilance are constitutive domain accent, making the abstraction domain-specific.

Translational Research is the proposed immediate parent. Analogy, Transfer Learning, Evidence Synthesis, Clinical Trial, Efficacy, and Adverse Drug Event describe supporting structures or evaluation outcomes.

The prospective queue contains one strict edge to domain_specific:translational_research. No live DAG mutation is authorized.

Relationships to Other Abstractions¶

Current abstraction Drug Repositioning Domain-specific

Parents (1) — more general patterns this builds on

Drug Repositioning is a kind of Translational Research Domain-specific

Translational Research is the proposed immediate parent.

Hierarchy paths (2) — routes to 2 parentless roots

Drug Repositioning → Translational Research → Translation and Conceptual Bridging → Representation → Abstraction

Show alternative path (1)

Neighborhood in Abstraction Space¶

Drug Repositioning sits in a sparse region of the domain-specific corpus (95^th percentile for distinctiveness): few abstractions share its structure, so a faithful description tends to retrieve it precisely.

Family — Unclustered & Miscellaneous (1565 abstractions)

Nearest neighbors

Adverse Event Prediction — 0.82
Continuous Individualized Risk Index — 0.79
Translational Research — 0.76
Elimination Diet — 0.76
Allelic Heterogeneity — 0.75

Computed from structural-signature embeddings · 2026-09-08

Not to Be Confused With¶

Off-label prescribing without a development program.
A new formulation with no new therapeutic use.
Generic manufacture or brand extension alone.
De novo discovery of an uncharacterized molecule.
A computational prediction treated as clinical evidence.
Prior approval treated as universal safety clearance.

References¶

[1] Ted T. Ashburn and Karl B. Thor, “Drug Repositioning: Identifying and Developing New Uses for Existing Drugs,” Nature Reviews Drug Discovery 3, 2004, 673–683. DOI 10.1038/nrd1468. registry ↩

[2] Sudeep Pushpakom et al., “Drug Repurposing: Progress, Challenges and Recommendations,” Nature Reviews Drug Discovery 18, 2019, 41–58. DOI 10.1038/nrd.2018.168. registry ↩a ↩b

[3] Natalia Novac, “Challenges and Opportunities of Drug Repositioning,” Trends in Pharmacological Sciences 34(5), 2013, 267–272. DOI 10.1016/j.tips.2013.03.004. registry ↩

[4] U.S. Food and Drug Administration, Applications Covered by Section 505(b)(2): Guidance for Industry, 1999. registry ↩